Skip to main content
S&P 5007,580.07-1.82%DOW51,770.31-1.09%NASDAQ25,437.00-2.86%BTC$77,892.00-0.12%ETH$2,284.26+0.69%GOLD$3,908.50+0.25%OIL$99.37-4.56%
Smart Investors Daily
SID Premium
VI

NASDAQ · VIVS

VivoSim Labs, Inc.

Healthcare · Biotechnology

$0.15

Down-$0.00 (-1.97%)

Updated Nov 2, 2026, 10:12 AM

SID Score

3.2/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
5.82M
P/E ratio
-2.81
Dividend yield
0.00%
52-week range
$0.14 – $1.96
Volume
755.87K
Avg. volume
510.14K

Price performance · VIVS

VIVS price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 30, 2026

VIVS closed at $0.15 after 20 trading sessions, down 25.10% for the selected period.

Last close
$0.15
Period change
-25.10%
Period low
$0.15
Period high
$0.21
Daily close
View OHLC price history
VIVS OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 30, 2026$0.1515$0.155$0.1423$0.1546755.87K
Oct 29, 2026$0.1471$0.1679$0.1468$0.15772.57M
Oct 28, 2026$0.1473$0.1513$0.142$0.1457320.07K
Oct 27, 2026$0.158$0.1598$0.1454$0.1503476.69K
Oct 26, 2026$0.146$0.1555$0.1417$0.152569.73K
Oct 23, 2026$0.1535$0.157$0.1442$0.1485746.05K
Oct 22, 2026$0.1819$0.1819$0.1531$0.15942.66M
Oct 21, 2026$0.162$0.1798$0.1612$0.1772.65M
Oct 20, 2026$0.16$0.1847$0.1592$0.1713692.3K
Oct 19, 2026$0.1591$0.1648$0.155$0.1575359.44K
Oct 16, 2026$0.163$0.169$0.1528$0.1569827.69K
Oct 15, 2026$0.157$0.19$0.1495$0.1713.52M
Oct 14, 2026$0.1686$0.1714$0.16$0.1609362.79K
Oct 13, 2026$0.1793$0.1793$0.172$0.1742182.3K
Oct 12, 2026$0.179$0.1821$0.169$0.1741.1M
Oct 9, 2026$0.1776$0.1836$0.168$0.1801334.51K
Oct 8, 2026$0.1944$0.1944$0.1746$0.1772872.72K
Oct 7, 2026$0.201$0.2075$0.1915$0.1915881.23K
Oct 6, 2026$0.2115$0.2115$0.2005$0.2019378.05K
Oct 5, 2026$0.1957$0.2119$0.1928$0.2064444.37K

Latest VIVS news

The latest Smart Investors Daily articles mentioning VIVS.

Stock researchCompany · Overview

VIVS research

Overview

Company profile and research snapshot.

Company profile

VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 21, 2026

VivoSim Labs Extends NAMkind Platform with Human Disease Models for Efficacy Testing and Mechanistic Biomarker Profiling

Patient-derived liver and intestinal disease models are designed to help drug developers test whether a candidate reduces human disease in tissue before it reaches clinical trialsSAN DIEGO, Oct. 21, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models for preclinical safety and efficacy, today announced that it is extending its human tissue platform beyond toxicology, the c

Yahoo · Oct 7, 2026

VivoSim Labs Celebrates Updated FDA Regulations Allowing Greater use of Non-Animal Testing Methods

As the FDA opens the door to non-animal safety testing, VivoSim's human-relevant models are already helping lower drug costsSAN DIEGO, Oct. 07, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models for preclinical safety, today celebrated the U.S. Food and Drug Administration's (FDA) direct final rule updating its regulations to clarify that non-animal methods can be used wh

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By